Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
Launched by PRO TOP & MEDIKING COMPANY LIMITED · Oct 1, 2007
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
To compare the safety and effectiveness in between oculusgen (ologen) collagen matrix implantation and Mitomycin-C(MMC) for glaucoma surgery. The surgery is performed by the gold standard of trabeculectomy. Mitomycin-C(MMC) is applied for those who not collagen matrix implanted.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Open angle glaucoma
- • Maxima anti-glaucoma medication failed
- • Age\>18
- • Able to complete the follow up
- Exclusion Criteria:
- • Topical eye inflammation
- • Angle closure glaucoma
- • Deformity glaucoma
- • One eye glaucoma
- • Previous conjunctiva opened
- • Allergy to collagen
About Pro Top & Mediking Company Limited
Pro Top & Mediking Company Limited is a distinguished clinical trial sponsor dedicated to advancing medical research and innovation. With a commitment to enhancing patient care, the company specializes in the development and execution of clinical trials across various therapeutic areas. Leveraging a team of experienced professionals and state-of-the-art technologies, Pro Top & Mediking ensures rigorous adherence to regulatory standards and ethical practices. The company collaborates with healthcare providers and research institutions to facilitate the discovery of novel treatments, ultimately aiming to improve health outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Koln, , Germany
Patients applied
Trial Officials
Thomas Dietlein, Ph. D, MD
Principal Investigator
Universität Köln
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials